Abbott India says to comply with government order on drugs ban
Add BT as a preferred source[NEW DELHI] US-pharmaceutical giant Abbott Laboratories' India unit will comply with all legal requirements of a government order that bans more than 300 combination drugs in the country, a company spokesman said on Monday.
India banned 344 drug combinations over the weekend, including Abbott's codeine-based cough syrup, after a government panel of experts found they had "no therapeutic justification".
Abbott's Phensedyl cough syrup accounts for about a third of the Indian cough syrup market, and its sales are estimated to make up more than 3 per cent of the company's US$1 billion India revenue.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Two-thirds of Sentosa Cove resales in the red, with average loss topping S$1 million since 2023
